Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
Table 2
Basal and stimulated LH, FSH, and E2 levels of patients and leuprolide acetate dose at the start and during the course of treatment (mean ± SD) (range).
Hormones
Initially ()
After treatment with GnRH analogue
3rd month ()
6th month ()
9th month ()
12th month ()
Basal LH (mIU/mL)
1.2 ± 1.7 (0.07–10.3)
0.2 ± 0.2 (0.07–1.1)
0.00
0.2 ± 0.1 (0.07–0.6)
0.00
0.2 ± 0.1 (0.07–0.6)
0.00
0.2 ± 0.1 (0.07–0.9)
0.00
Peak LH (mIU/mL)
9.2 ± 9.0 (3.8–48.8)
2.0 ± 1.4 (0.4–8.4)
0.00
1.7 ± 1.1 (0.3–6.0)
0.00
1.6 ± 0.7 (0.1–4.2)
0.00
1.5 ± 0.6 (0.4–2.9)
0.00
Basal FSH (mIU/mL)
3.7 ± 2.1 (0.7–8.9)
2.2 ± 1.1 (0.4–4.3)
0.00
2.3 ± 1.0 (0.4–3.7)
0.00
2.3 ± 0.9 (0.2–3.3)
0.00
2.7 ± 0.7 (1.1–5.1)
0.15
E2 (pg/mL)
27.6 ± 14.9 (3.8–68.7)
17.0 ± 6.9 (7.0–32.6)
0.00
17.0 ± 7.4 (7.0–36.9)
0.00
15.6 ± 7.1 (7.0–33.7)
0.00
14.2 ± 7.4 (7.0–39.8)
0.00
Leuprolide acetate dose (mg/kg/28 days)
0.12 ± 0.03 (0.04–0.23)
0.13 ± 0.05 (0.04–0.33)
0.03
0.12 ± 0.04 (0.04–0.32)
0.00
0.12 ± 0.05 (0.04–0.31)
0.00
0.12 ± 0.04 (0.04–0.32)
0.00
The value represents the difference according to value before treatment.
